[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors",
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=5fc2a8a9239b27e1616df2d823adefd781bed007a92e1f011806c81bb4e3ede1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734389117,
      "headline": "Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors",
      "id": 132018673,
      "image": "https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=5fc2a8a9239b27e1616df2d823adefd781bed007a92e1f011806c81bb4e3ede1"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Johnson & Johnson Sues Cigna Units Over Alleged Drug Fund Misuse",
    "summary": "Johnson & Johnson (JNJ) is suing Cigna's divisions, Express Scripts and Accredo, claiming they worke",
    "url": "https://finnhub.io/api/news?id=c3beaaceebb4bb22fa36dd32e15f52a89cb3380c2622e2e194f3a74f648f422f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734375930,
      "headline": "Market Chatter: Johnson & Johnson Sues Cigna Units Over Alleged Drug Fund Misuse",
      "id": 132015732,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) is suing Cigna's divisions, Express Scripts and Accredo, claiming they worke",
      "url": "https://finnhub.io/api/news?id=c3beaaceebb4bb22fa36dd32e15f52a89cb3380c2622e2e194f3a74f648f422f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Monday when compared to competitors",
    "summary": "Johnson & Johnson stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f1ef80d76d5a2b51971174c3b06decdb5125dc648ed712d0eb5308b2a0408d78",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734366660,
      "headline": "Johnson & Johnson stock underperforms Monday when compared to competitors",
      "id": 132064824,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f1ef80d76d5a2b51971174c3b06decdb5125dc648ed712d0eb5308b2a0408d78"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 111-point drop led by losses for UnitedHealth, Verizon shares",
    "summary": "Dow's 111-point drop led by losses for UnitedHealth, Verizon shares",
    "url": "https://finnhub.io/api/news?id=b19113b4252df7683d22d1790a148b167c7d01ac120864d66f09a3e6c3766695",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734364320,
      "headline": "Dow's 111-point drop led by losses for UnitedHealth, Verizon shares",
      "id": 132064825,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow's 111-point drop led by losses for UnitedHealth, Verizon shares",
      "url": "https://finnhub.io/api/news?id=b19113b4252df7683d22d1790a148b167c7d01ac120864d66f09a3e6c3766695"
    }
  },
  {
    "ts": null,
    "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
    "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
    "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734351780,
      "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
      "id": 132011828,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
      "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87"
    }
  },
  {
    "ts": null,
    "headline": "PFA to surpass radiofrequency ablation in 2025: Citi survey",
    "summary": "Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as Medtronic, Boston Scientific and Johnson & Johnson battle for market share.",
    "url": "https://finnhub.io/api/news?id=a52cacf004c35f4b122a6b453ab24524042d7b25cdbb2daddd11f4458e05ca4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734351171,
      "headline": "PFA to surpass radiofrequency ablation in 2025: Citi survey",
      "id": 132015319,
      "image": "https://imgproxy.divecdn.com/q3o076EExkKsEqYqme3_fAelP6tkkQT0AR0DEtz8ThI/g:nowe:501:123/c:1773:1002/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9NZWR0cm9uaWNfQWxsX2luX09uZV9NZWR0cm9uaWNfU3BoZXJlXzlfQ2F0aGV0ZXItX0FmZmVyYS5qcGc=.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as Medtronic, Boston Scientific and Johnson & Johnson battle for market share.",
      "url": "https://finnhub.io/api/news?id=a52cacf004c35f4b122a6b453ab24524042d7b25cdbb2daddd11f4458e05ca4c"
    }
  },
  {
    "ts": null,
    "headline": "J&J: applies to the FDA for an expanded indication for Simponi",
    "summary": "Johnson & Johnson announced today that it has applied to the U.S. Food & Drug Administration for expanded approval of Simponi for the treatment of children aged 2 and over with moderately to severely...",
    "url": "https://finnhub.io/api/news?id=2de924fa59c06ee0e270c8f6c7ef60f9e24b4e186371e53d9db9f697224fde2d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734339857,
      "headline": "J&J: applies to the FDA for an expanded indication for Simponi",
      "id": 132011044,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced today that it has applied to the U.S. Food & Drug Administration for expanded approval of Simponi for the treatment of children aged 2 and over with moderately to severely...",
      "url": "https://finnhub.io/api/news?id=2de924fa59c06ee0e270c8f6c7ef60f9e24b4e186371e53d9db9f697224fde2d"
    }
  }
]